GPC3 and neoplasm: Meantime, we found that OHSV2-DSTEFAP/CD3-based therapy exhibits the absence of off-tumor toxicity, including cytokine storm, inconsistent with previous studies on FAP targeting therapy and CAR-T therapy, despite GPC3 and FAP are suboptimal targets owing to their low specificity (45, 46).